Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 1;131(11):e149414.
doi: 10.1172/JCI149414.

How elite controllers and posttreatment controllers inform our search for an HIV-1 cure

Affiliations
Review

How elite controllers and posttreatment controllers inform our search for an HIV-1 cure

Jonathan Z Li et al. J Clin Invest. .

Abstract

A small percentage of people living with HIV-1 can control viral replication without antiretroviral therapy (ART). These patients are called elite controllers (ECs) if they are able to maintain viral suppression without initiating ART and posttreatment controllers (PTCs) if they control HIV replication after ART has been discontinued. Both types of controllers may serve as a model of a functional cure for HIV-1 but the mechanisms responsible for viral control have not been fully elucidated. In this review, we highlight key lessons that have been learned so far in the study of ECs and PTCs and their implications for HIV cure research.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: JZL has consulted for Abbvie and JanBiotech.

Figures

Figure 1
Figure 1. Virologic and immunologic profiles of CPs, ECs, and PTCs.
ART is normally started in chronic progressors (CPs) during the chronic phase of infection, and a rebound in viremia is seen when therapy is discontinued. In contrast, elite controllers (ECs) are ART-naive subjects who control viral replication naturally. Posttreatment controllers (PTCs) are more often patients in whom ART is initiated during primary infection. These patients maintain control of viral replication when ART is discontinued. *Estimates depend on definition of EC and PTC. +, ++, and +++ indicate relative magnitude of each parameter.

Similar articles

Cited by

References

    1. Cao Y, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995;332(4):201–208. doi: 10.1056/NEJM199501263320401. - DOI - PubMed
    1. Hogervorst E, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis. 1995;171(4):811–821. doi: 10.1093/infdis/171.4.811. - DOI - PubMed
    1. Lisziewicz J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340(21):1683–1684. doi: 10.1056/NEJM199905273402114. - DOI - PubMed
    1. Li JZ, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016;30(3):343–353. - PMC - PubMed
    1. Jessen H, et al. How a single patient influenced HIV research—15-year follow-up. N Engl J Med. 2014;370(7):682–683. doi: 10.1056/NEJMc1308413. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances